Hi DDD24,In my opinion, your question was more relevant before...

Hi DDD24,

In my opinion, your question was more relevant before the results started coming in. WIth that being said, there is certainly a possible outcome where the expansion trial shows CF33 to yield no benefit compared to the current SOC. But how probable is that outcome? I believe it to be less than 50%. But dont take my word for it, my thoughts come from the FDA granting CF33 fast track designation.

We know that CF33 is working in many different patients. Every one of the trial patients had progressed on at least two lines of therapy; the CR was four lines of treatment if my memory serves me. So, at this point, more data will serve to strengthen and build upon current results. Keeping in mind all current results have been achieved at lower-mid doses. So, we will probably see even better results in subsequent data readouts.

Devils advocate if results do not get any better and are constant, then we still have a drug that's stopped cancer growth in the majority of these patients who were non-responders to current SOC, with little to no side effects; that's significant.

Cheers.